Cambridge, UK–based biotechnology company focused on the discovery and development of innovative cancer therapies for patients with significant unmet medical needs. Founded in 2005, the company specializes in creating highly selective small-molecule drug candidates targeting primary brain tumours and cancers that frequently metastasize to the brain. Sentinel Oncology combines expertise in medicinal chemistry, cancer biology, and drug development to advance a pipeline of targeted oncology treatments, with several late-stage preclinical and clinical-stage programs. Through strategic collaborations with pharmaceutical and biotechnology partners, the company aims to improve survival outcomes and quality of life for cancer patients by delivering novel, precision-based therapeutics.